FTC Affiliate Disclosure: This article may contain affiliate links. If you enroll through a link in this article, a commission may be earned at no additional cost to you. This does not influence the information presented.
If you are reading this, you probably searched for something like “MEDVi reviews,” “is MEDVi worth it,” or “MEDVi GLP-1 2026.” Maybe you saw the viral New York Times article about a solo founder building a billion-dollar telehealth company with AI. Maybe you saw headlines about FDA warnings. Maybe a friend told you she lost 20 pounds on MEDVi's program. Maybe you saw all three and have no idea what to think.
This guide is for you. Not a sales pitch. Not a takedown piece. A clear-eyed look at what MEDVi is, what the current situation involves, and what you need to think about before making a decision about any telehealth GLP-1 program in 2026.
The Quick Version
MEDVi is a telehealth platform that connects patients with licensed clinicians who can prescribe GLP-1 weight-loss medications — mainly compounded semaglutide and tirzepatide. Matthew Gallagher launched the company in September 2024 with $20,000 and a stack of AI tools. It scaled to $401 million in first-year revenue, a figure the New York Times verified by reviewing the company's financials. MEDVi currently claims more than 500,000 patients.
The company is LegitScript certified and has more than 11,400 Trustpilot reviews with a 4.4 to 4.5 average rating. Compounded semaglutide injections start at $179 for the first month, then $299 per month for refills. Compounded tirzepatide injections are $349 per month. Oral GLP-1 tablets start at $249 per month. All pricing is cash-pay — no insurance.
At the same time, MEDVi received an FDA warning letter in February 2026 for misbranding on its website. Its clinical partner OpenLoop Health experienced a data breach that may have affected 1.6 million patients. There are pending lawsuits involving questions about compounded oral tirzepatide efficacy. And the FDA has warned more than 30 telehealth companies in the same space for similar issues.
Both realities exist at the same time. Your job as a consumer is to understand both before you make a decision.
What MEDVi Gets Right
Being fair requires acknowledging what the company has done well — and there are legitimate positives:
Pricing and accessibility. MEDVi's compounded semaglutide starting at $179 per month is among the lowest entry prices in the market. For consumers who cannot afford branded Wegovy at $1,000 or more per month without insurance — and who cannot get insurance to cover it — this pricing represents real access to medications that clinical research has shown to be effective for weight loss. The $179 price point undercuts Hims (around $199), Henry Meds ($197 to $297), and Ro ($199 to $349 for branded paths).
Convenience. The fully online process — health assessment, clinician evaluation, prescription, and home delivery — removes barriers that keep many patients from seeking weight-management treatment. For patients in rural areas, patients with mobility challenges, or people who experience stigma in traditional healthcare settings, this accessibility has real value.
Volume of positive experiences. More than 11,000 Trustpilot reviewers have given MEDVi positive ratings. The themes come up over and over: appetite suppression that works, measurable weight loss, fast medication delivery, and an easy enrollment process. Review platforms have their biases, and any company can cherry-pick testimonials. But the sheer volume of positive feedback suggests that many patients are receiving medication, experiencing the expected effects, and finding value in the service.
LegitScript certification. This independent verification is not a rubber stamp. LegitScript evaluates telehealth companies against compliance standards covering licensing, regulatory adherence, and operational transparency. Companies that are purely fraudulent cannot pass these checks. MEDVi's active certification is a real legitimacy signal — not a guarantee that everything is perfect, but meaningful evidence that the company is not a fly-by-night operation.
Disclosure of compounding status. MEDVi does disclose — on its website — that compounded GLP-1 medications are not FDA-approved finished products. This disclosure matters for informed consent. Not every competing platform is equally up-front about this distinction.
What Raises Legitimate Concern
Being fair also means acknowledging the concerns — and they are real:
The FDA warning letter. Received February 20, 2026, the letter identified misbranding violations related to marketing language. The FDA found that MEDVi's website falsely implied FDA approval of compounded products and misrepresented who compounds the medications. Warning letters are advisory rather than punitive — but they represent the FDA formally telling a company that its marketing practices do not meet regulatory standards. MEDVi joins more than 30 other telehealth companies that received similar warnings. That context matters. But the warnings themselves should be taken seriously regardless.
Infrastructure partner challenges. OpenLoop Health's January 2026 data breach and the pending class-action litigation against OpenLoop and Triad Rx create real uncertainty for patients whose care is processed through these partners. MEDVi did not cause the data breach and is not a defendant in the primary class action. But its patients may be affected because the three-part telehealth model means patient risk extends beyond the brand they signed up with.
The oral tirzepatide question. The scientific argument that compounded oral tirzepatide tablets may lack a viable absorption pathway is a real pharmacological concern. It is not a competitive talking point from branded drug manufacturers. The only FDA-approved oral GLP-1 product needed a specialized absorption enhancer to achieve just 1 percent bioavailability. Whether compounded oral tirzepatide reaches therapeutic levels without that kind of technology is a question that no published clinical evidence has answered. Patients on oral tirzepatide from any compounding source should ask their prescribing clinician about this directly.
Advertising practices. The documented use of fictitious personas with fabricated medical titles in Facebook advertising, AI-generated before-and-after images, and the sheer volume of ads (more than 5,000 on Meta's platform) raises fair questions about the standards MEDVi applies to its marketing. The company includes disclaimers. But critics — including state attorneys general who addressed AI-generated weight-loss advertising in a December 2025 letter to Meta — have asked whether disclaimers are enough when the advertising itself is designed to suggest medical authority.
Billing complaints. Auto-renewal confusion, shifting refund guarantee terms, and difficult cancellation processes are well-documented in consumer reviews across multiple platforms. Some customers report that the money-back guarantee period changed from 3 months to 5 months after they enrolled. Others report being denied refunds because they had “fluctuated by 1 pound.” These patterns affect consumer trust and can hit people's finances. They are not unique to MEDVi — most subscription telehealth platforms face similar complaints — but that does not make them acceptable.
The Bigger Picture: The Compounded GLP-1 Market Is Changing Fast
The MEDVi story cannot be separated from the broader changes hitting the telehealth GLP-1 market in 2026:
Drug shortage status is shifting. The legal basis for much compounding activity rests on FDA-recognized drug shortages. As Novo Nordisk and Eli Lilly increase manufacturing capacity, certain formulations are coming off the shortage list. That could affect the legal availability of compounded versions — at MEDVi and across the industry.
Branded manufacturers are going on offense. Novo Nordisk filed a patent infringement lawsuit against Hims in early 2026. Similar actions could spread to other compounded GLP-1 providers.
The FDA is moving from advisory to enforcement mode. The jump from individual warning letters to the March 2026 batch of 30-plus letters suggests the agency is getting ready for more serious action. Companies that do not address the issues in their warning letters may face seizure or injunction down the road.
These pressures affect every compounded telehealth GLP-1 provider, not just MEDVi. Consumers who enroll in any compounded GLP-1 program should understand that the rules underneath these programs may shift while you are mid-treatment.
How MEDVi Compares to the Main Alternatives
If you are comparison shopping, here is where MEDVi sits relative to the other major telehealth GLP-1 providers:
Hims & Hers: Compounded semaglutide starting around $199 per month. Also offers FDA-approved Wegovy. Publicly traded with a larger customer service team. Faces its own legal challenges including a Novo Nordisk patent suit. More review volume and generally fewer billing complaints than MEDVi.
Ro: Branded Wegovy from $199 for the first two months, then $349 per month. Also offers compounded options. Does a better job of clearly separating its brand-name and compounded product lines. Better choice if you specifically want FDA-approved medication.
Henry Meds: Compounded semaglutide at $197 to $297 per month. Lower complaint volume around billing and refunds. Smaller overall customer base than MEDVi.
MEDVi: Lowest entry price at $179 per month for compounded semaglutide. Recently added brand-name Wegovy and Zepbound paths. The company has also expanded into men's health with its QUAD compounded ED formula — for a detailed practitioner-level review of that product, see our MEDVi QUAD 2026 compounded ED formula practitioner review. Highest review volume but also highest billing complaint volume among these four providers. The most media attention of any telehealth GLP-1 company in April 2026 — for better and worse.
What to Do With All of This Information
If you are considering MEDVi or any telehealth GLP-1 program, here is the most practical advice this analysis can offer:
Talk to your doctor first. A telehealth assessment — no matter how good — does not replace the relationship with a physician who knows your full medical history, your current medications, and your overall health picture. GLP-1 medications have real contraindications and side effects that call for a full clinical evaluation.
Understand what you are getting. If you enroll in a compounded GLP-1 program, you are receiving a medication that is not FDA-approved as a finished product. This is not a disqualifying fact by itself. But it is a fact you should understand and accept before you proceed.
Read the billing terms all the way through. The most common consumer complaints about MEDVi and similar platforms involve billing surprises. Read the auto-renewal policy. Note the 72-hour cancellation window. Understand the refund guarantee terms — including the current 5-month requirement and what “significant weight loss” means in their policy. Know what you are agreeing to before you enter your credit card number.
Verify independently. Check the platform's LegitScript certification status at legitscript.com. Look up listed physicians through your state's medical board website. Review the current FDA warning letter status through the FDA's public database at fda.gov.
Watch the regulatory situation. The compounded GLP-1 market is changing fast. What is available today may not be available next month. Stay informed about FDA enforcement actions and drug shortage list updates that could affect your medication access.
Do not make healthcare decisions based on headlines. Not the growth headlines. Not the controversy headlines. Neither one should be the primary input into your decision. Your health profile, your doctor's recommendation, and your own informed evaluation of the risks and benefits should drive this choice.
One More Thing
MEDVi is neither the miracle of AI-powered healthcare that the growth story suggests nor the cautionary tale of telehealth gone wrong that the regulatory story implies. It is a real company, serving real patients, with real credentials and real unresolved challenges — operating in a market that is moving under everyone's feet right now.
The consumers who will come out of this best are those who approach every option — MEDVi included — with informed caution, verified facts, and the involvement of a doctor they trust.
Frequently Asked Questions
Is MEDVi worth it in 2026?
That depends on your priorities. MEDVi offers the lowest entry price for compounded semaglutide at $179 per month. Many patients report positive weight-loss results. The company has legitimate certifications and licensed providers. However, MEDVi also faces an FDA warning letter, billing complaints, and regulatory uncertainty. If low cost is your top priority and you are comfortable with compounded medications and the current regulatory situation, MEDVi may work for you. If you want FDA-approved medication or a provider with fewer consumer complaints, consider Ro or Hims instead.
What is the cheapest telehealth GLP-1 option right now?
Among major providers, MEDVi's compounded semaglutide at $179 per month for the first month is the lowest entry price. Henry Meds starts at $197. Hims starts around $199. Ro starts at $199 for branded Wegovy. Keep in mind that first-month pricing is not the ongoing cost — MEDVi's refills run $299 per month, which narrows the gap with competitors.
Can I get FDA-approved Wegovy through MEDVi?
MEDVi has recently added brand-name Wegovy and Zepbound paths through a $99 membership plus the cost of the medication itself. However, MEDVi built its business primarily around compounded medications, and the brand-name options are a newer addition. If getting FDA-approved medication is important to you, Ro may offer a clearer and more established path to that option.
Is MEDVi safe?
MEDVi's clinical care is provided by licensed clinicians through the OpenLoop Health and CareValidate networks. The medications contain the same active ingredients as FDA-approved GLP-1 drugs. The platform holds LegitScript certification. However, the medications are compounded — meaning they are not individually reviewed by the FDA for safety, efficacy, or quality. The FDA has flagged marketing practices at MEDVi and more than 30 other telehealth companies. The safest approach is to discuss your options with your personal physician before enrolling in any program.
What is the MEDVi cancellation policy?
MEDVi programs auto-renew. You must cancel at least 72 hours before your next billing date to avoid being charged for the next cycle. The company offers a money-back guarantee, but consumers have reported that the guarantee period was extended from 3 to 5 months and that even small weight fluctuations were used to deny refund eligibility. Read the current terms on the official website before enrolling.
Did the New York Times verify MEDVi's revenue claims?
Yes. The Times reported that it was given access to MEDVi's financial records and verified $401 million in 2025 sales with a 16.2 percent net profit margin. The $1.8 billion figure is a 2026 projection — not a verified result. Whether MEDVi reaches that target depends on growth, regulatory developments, and market conditions.
What is Matthew Gallagher's background?
Gallagher is a 41-year-old self-taught entrepreneur from Los Angeles. He launched MEDVi in September 2024 with $20,000 in personal savings and used AI tools to build and operate the platform. His brother Elliot is the company's only other full-time employee. Gallagher has described MEDVi as “the fastest growing company in history” on LinkedIn — a claim that has not been independently verified.
What should I do if I had a bad experience with MEDVi?
Contact MEDVi directly at hello@medvi.org or by phone at (323) 690-1564. If you cannot resolve your issue directly, you can file a complaint with the Better Business Bureau, the Federal Trade Commission at ftc.gov, your state attorney general's office, or the FDA through the MedWatch reporting system if your concern involves medication safety.
This article is for informational purposes only. It does not constitute medical, legal, or financial advice. GLP-1 medications are prescription medications that require clinical evaluation. Compounded medications are not FDA-approved finished products. Consult licensed professionals before making healthcare decisions.
NewEasternHealth.com Editorial Team | Published April 2026